An interventional study of PIRF measured by InCheck DIAL and Regular treament in Chronic Obstructive Pulmonary Disease, sponsored by Shanghai Zhongshan Hospital. Status unknown at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-08-20.
Sponsored by Shanghai Zhongshan Hospital · Not applicable, Interventional, and Treatment
This study is designed to determine whether the optimized inhalation therapy based on peak inspiratory flow rates (PIFR) measured against the simulated resistance can reduce the rate of treatment failure in patients recovering from acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Errors in inhaler use and quality of life are also to be evaluated.
The study will recruit 460 patients with AECOPD whose exacerbated symptoms are relieved by 5-7 days of standard therapy. The participants are divided into PIFR group and control group in a 1:1 ratio according to a random number table method. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA） (budesonide/ formoterolSymbicort turbuhaler® 160/4.5 μg bid or Beclometasone/ Formoterol Foster® pressure metered dose inhaler(pMDI) 100/6 μg 2 puff bid). For symptomatic patients before acute exacerbation, Spiriva handihaler® 18μg qd or Spiriva respimat® 2.5μg qd will be prescribed in combination with ICS/LABA. For PIFR group, PIFR is measured by InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). If PIFR is less than 60L/min , the patient will be given pMDI with spacer. If PIFR value is over 60 L/min, the patient will be given dry powder inhaler(DPI).). The control group will be given DPI or pMDI with spacer according to the judgment of a respiratory physician. Both groups will be taught to use the device after the prescription, and then be reminded to use medication via a WeChat public account.
The primary endpoint of the study is the 30-day treatment failure including AECOPD recurrence resulting in an emergency visit, admission, or need for intensified medication). The secondary endpoints of the study are the error rate of inhalation device use, satisfaction with inhalation devices, symptoms and quality of life, 30-day mortality, chronic obstructive pulmonary diseases(COPD)-related treatment costs and PIFR.
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's planned enrollment of 460 is above the median of 72 across 2,118 interventional studies indexed under Lung Diseases.
Browse Lung Diseases studies →Shanghai Zhongshan Hospital is the lead sponsor of 636 studies on the registry; 283 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: PIRF measured by InCheck DIAL
Drug: Regular treament
Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
30-day treatment failure rate
Treatment failure means AECOPD recurrence resulting in an emergency visit, admission, or need for intensfied medication.
Time frame: 30 days
the error rate of inhalation device use
Time frame: 30 days/ 90 days
satisfaction with inhalation devices
Patients' satisfaction with inhalation devices will be assessed by the following items. If the patient meets any of the following, the result will be unsatisfactory: 1. The patient has forgotten to use the inhaler. 2. The patient has forgotten to use the inhaler in the last two weeks. 3. The patient has reduced the frequency of using inhaler without medical advice. 4. The patient has forgotten to bring an inhaler when traveling or leaving home. 5. The patient has quitted the inhaler without medical advice when feeling his condition improved. 6. The patient has felt it difficult to comply with the COPD treatment plan. 7. The patient has felt it difficult to use the inhaler.
Time frame: 30 days/ 90 days
score of St.George's Respiratory Questionnaire(SGRQ)
St.George's Respiratory Questionnaire(SGRQ) is used to assess patient's quality of life. The SGRQ scale range is from 0 to 100. The higher the score is, the more severe the impact of COPD on patient' life is.
Time frame: 30 days/ 90 days
30-day mortality
Time frame: 30 days
COPD-related treatment costs
Time frame: 30 days/ 90 days
Peak Inspiratory Flow Rates（PIFR）
Time frame: 30 days/ 90 days
90-day mortality
Time frame: 90 days
score of modified British medical research council(mMRC)
Modified British medical research council(mMRC) is used to assess patient's symptoms. The mMRC scale range is from 0 to 4. The higher the score is, the more severe the patient's dyspnea is.
Time frame: 30 days/ 90 days
score of COPD assessment test(CAT)
COPD assessment test(CAT) is used to assess patient's symptoms. The CAT scale range is from 0 to 40. A score of 0-10 indicates the patient is slightly affected by COPD. A score of 11-20 indicates the patient is moderately affected by COPD. A score of 21-30 indicates the patient is seriously affected by COPD. A score of 31-40 indicates the patient is extremely affected by COPD.
Time frame: 30 days/ 90 days
Plan to share: No
This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Zhongshan Hospital